Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cuprina Holdings (Cayman) Limited Class A ( (CUPR) ) has provided an update.
On November 18, 2025, Cuprina Holdings announced a joint venture with Aiodine Laboratory to develop and market a novel iodine-based solution for wound care therapy. This partnership aims to utilize Aiodine’s proprietary iodine technology to create antiseptic solutions for chronic and acute wounds, with plans to begin clinical studies for regulatory approval in 2026. Cuprina will handle global sales and marketing, while Aiodine provides technical expertise. The iodine solution has shown promising results in a study, indicating significant wound healing and reduced infection, potentially positioning Cuprina to expand its offerings in the growing wound care market, valued at $21 billion in 2024 and projected to reach $36 billion by 2032.
More about Cuprina Holdings (Cayman) Limited Class A
Cuprina Holdings (Cayman) Limited is a Singapore-based biomedical and biotechnology company focused on developing and commercializing innovative products for managing chronic wounds and operating in the health and beauty sectors. The company leverages its expertise in biomedical research to create wound care products from natural sources that meet international standards.
Average Trading Volume: 1,692,813
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.41M
Learn more about CUPR stock on TipRanks’ Stock Analysis page.